Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024

  • Product Code:
    RP-ID-10078107
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    121
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Biologics Market – Drivers, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.
The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.
Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.
Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.
Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.
Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.
Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 11
1.2.1 R&D pipeline in pharmaceutical industry 11
1.2.2 Top pharma drugs by sales in 2017 ($Million) 13
2 Report Outline 16
2.1 Report Scope 16
2.2 Report Summary 16
2.3 Research Methodology 17
2.4 Report Assumptions 17
3 Market Snapshot 19
3.1 Market Definition – Infoholic Research 19
3.2 Biologics patent expiration in US and Europe (2010-2020) 19
3.3 Segmented Addressable Market (SAM) 19
3.4 Trends of the biologics market 20
3.5 Related Markets 21
3.5.1 Over the counter drugs 21
3.5.2 Orphan drugs 22
3.5.3 Human Insulin 23
4 Market Outlook 25
4.1 Market segmentation 25
4.2 PEST Analysis 26
4.3 Porter 5(Five) Forces 27
5 Market Characteristics 28
5.1 DRO – Global Biologics Market Dynamics 28
5.1.1 Drivers 28
5.1.1.1 Growing incidence of disease across the globe 28
5.1.1.2 Increasing number of biologics approvals 29
5.1.2 Opportunities 30
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials 30
5.1.2.2 Increasing opportunities in emerging markets 31
5.1.3 Restraints 32
5.1.3.1 Challenges associated with biologics production 32
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars 33
5.2 DRO – Impact Analysis 33
5.3 Key Stakeholders 35
6 Products: Market Size & Analysis 36
6.1 Overview 36
6.2 Monoclonal antibodies 37
6.3 Recombinant proteins/Hormones 39
6.4 Vaccines 40
6.5 Cell and Gene Therapy 42
6.6 Others 43
7 Applications: Market Size & Analysis 45
7.1 Overview 45
7.2 Cancer 46
7.3 Immunological disorders 46
7.4 Infectious disease 47
7.5 Hematologic disorders 47
7.6 Cardiovascular disease 48
7.7 Others 48
8 Regions: Market Size and Analysis 49
8.1 Overview 49
8.2 North America 50
8.2.1 US 50
8.2.2 Canada 51
8.3 Europe 51
8.3.1 UK 52
8.3.2 Germany 53
8.3.3 France 53
8.3.4 Spain 53
8.4 Asia Pacific 54
8.4.1 India 54
8.4.2 China 55
8.4.3 Japan 55
8.5 Rest of the World 55
9 Competitive Landscape 57
9.1 Overview 57
10 Vendor Profiles 60
10.1 F. Hoffmann-La Roche 60
10.1.1 Overview 60
10.1.2 Business Unit 63
10.1.3 Geographic Presence 63
10.1.4 Business Focus 64
10.1.5 SWOT Analysis 64
10.1.6 Business Strategy 65
10.2 Sanofi S.A. 66
10.2.1 Overview 66
10.2.2 Business Units 70
10.2.3 Geographic Presence 71
10.2.4 Business Focus 71
10.2.5 SWOT Analysis 72
10.2.6 Business Strategies 72
10.3 Amgen Inc. 73
10.3.1 Overview 73
10.3.2 Geographic Presence 77
10.3.3 Business Focus 77
10.3.4 SWOT Analysis 79
10.3.5 Business Strategies 80
10.4 Novo Nordisk A/S 81
10.4.1 Overview 81
10.4.2 Business Units 84
10.4.3 Geographic Presence 85
10.4.4 Business Focus 85
10.4.5 SWOT Analysis 86
10.4.6 Business Strategies 86
10.5 AbbVie Inc. 87
10.5.1 Overview 87
10.5.2 Geographic Presence 90
10.5.3 Business Focus 90
10.5.4 SWOT Analysis 91
10.5.5 Business Strategies 91
10.6 Johnson & Johnson 92
10.6.1 Overview 92
10.6.2 Business Units 96
10.6.3 Geographic Revenue 96
10.6.4 Business Focus 97
10.6.5 SWOT Analysis 98
10.6.6 Business Strategies 98
10.7 Novartis AG 99
10.7.1 Overview 99
10.7.2 Business Units 102
10.7.3 Geographic Revenue 103
10.7.4 Business Focus 104
10.7.5 SWOT Analysis 104
10.7.6 Business Strategies 105
11 Companies to Watch for 106
11.1 Bristol-Myers Squibb 106
11.1.1 Overview 106
11.2 GlaxoSmithKline plc 108
11.2.1 Overview 108
11.3 Merck & Co. 110
11.3.1 Overview 110
11.4 Eli Lilly and Company Ltd. 111
11.4.1 Overview 111
11.5 Teva Pharmaceutical Industries Ltd. 113
11.5.1 Overview 113
11.6 AstraZeneca PLC 114
11.6.1 Overview 114
11.7 Takeda pharmaceuticals 117
11.7.1 Overview 117
Annexure 120
 Acronyms 120

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports